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Subunit viral vaccines are typically not as efficient as live attenuated or inactivated vaccines at inducing 
protective immune responses. This paper describes an alternative ‘biomimetic’ technology; whereby 
viral antigens were formulated around a polymeric shell in a rationally arranged fashion with a surface 
glycoprotein coated on to the surface and non-structural antigen and adjuvant encapsulated. We 
evaluated this model using BVDV E2 and NS3 proteins formulated in poly-(D, L-lactic-co-glycolic 
acid) (PLGA) nanoparticles adjuvanted with polyinosinic:polycytidylic acid (poly(I:C) as an adjuvant 
(Vaccine-NP). This Vaccine-NP was compared to ovalbumin and poly(I:C) formulated in a similar 
manner (Control-NP) and a commercial adjuvanted inactivated BVDV vaccine (IAV), all inoculated 
subcutaneously and boosted prior to BVDV-1 challenge. Significant virus-neutralizing activity, and E2 
and NS3 specific antibodies were observed in both Vaccine-NP and IAV groups following the booster 
immunisation. IFN-γ responses were observed in ex vivo PBMC stimulated with E2 and NS3 proteins 
in both vaccinated groups. We observed that the protection afforded by the particulate vaccine was 
comparable to the licenced IAV formulation. In conclusion, the biomimetic particulates showed a 
promising immunogenicity and efficacy profile that may be improved by virtue of being a customisable 
mode of delivery.
Recently there has been a growing interest in using viral vectors or virus-like particles (VLPs) expressing heter-
ologous antigens to induce T cell and B cell responses. Viral vectors are recombinant, attenuated viruses which 
express an antigen of interest following infection1, whereas, VLPs are self-assembling viral structural proteins 
tagged with antigen2. Viral vectors afford the opportunity to deliver antigen intracellularly, thus enabling direct 
access to the cytosolic MHC class I pathway3. Furthermore, they are inherently immunostimulatory, express-
ing pathogen-associated molecular patterns (PAMPs) that engage with pattern recognition receptors to enhance 
the induction of antigen-specific responses4. VLPs on the other hand display antigenic protein on the parti-
cle surface in a uniform and repeated fashion, which enhances activation of antigen-specific B cell receptors5. 
Together these approaches represent the next-generation of vaccines. However, this paper describes a third 
approach; ‘biomimetic’ particle vaccines, which have the advantages of both a viral vector and a VLP. In their 
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simplest form biomimetic particles are polymeric particles, typically made of an inert polymer such as poly-(D, 
L-lactic-co-glycolic acid) (PLGA) or polycaprolactone (PCL), which encapsulate or are coated in antigen plus 
an immunostimulatory molecular adjuvant6–8. Biomimetic particles therefore provide a finely tuneable system, 
which allows for the spatial arrangement of multiple antigens whilst also accounting for nature of the immune 
response required through the incorporation of defined PAMPs.
We developed this approach by rationally designing a particle composed of a polymeric shell encapsulating a 
viral protein which is known to be a T cell target; often a non-structural protein only present during the intracel-
lular viral replication cycle. Encapsulated protein has previously been shown to be efficiently cross-presented by 
MHC class I9. As well as antigen, a viral-associated nucleic acid PAMP, in this case polyinosinic-polycytidylic acid 
(poly(I:C)), is co-encapsulated as a surrogate for immune-stimulation provided by the replicating viral genome. 
Poly(I:C) is a synthetic double stranded RNA analogue that is an agonist for endosomal TLR-3 and the cyto-
solic receptors retinoic acid inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA-5) and 
DNA-dependent protein kinase catalytic subunits (DNA-PKcs)10. Poly(I:C) is a strong inducer of IL-12 and type 
I IFN thus enhancing dendritic cell (DC) maturation and polarizing antiviral T cell and antibody responses11. 
Co-delivery of PAMPs and antigen in biodegradable nanoparticles has been shown to enhance both T cell and 
humoral responses compared to inoculation of soluble antigen and TLR agonists12,13. In addition to the encapsu-
lated payload, a second antigen, which is the major antibody target; often a viral envelope glycoprotein, is coated 
onto the surface of particles. Coating particles with antigen, as opposed to encapsulation of antigen, has shown to 
improve antibody responses by increasing antigen availability for engagement with B cell receptors14. The parti-
cles should fall roughly into the sub-micron size range, giving them access to the draining lymph nodes as well as 
an enhanced ability to be taken up by DCs15. DCs should be considered the key target in this approach, positioned 
at the interface of innate and adaptive system, they are the major professional antigen-presenting cells of the 
immune system, unparalleled in their ability to prime naïve T cells16. The shell of the particle here will be com-
posed of PLGA, which is an innocuous polymer routinely used in drug delivery formulation which has been used 
pre-clinically as a vehicle for the delivery of antigens for human and veterinary applications17,18. Furthermore, 
PLGA particles have also been shown to be inherently immunogenic, activating the inflammasome and therefore 
driving the innate immune responses required for the induction of adaptive immunity19. Previous descriptions 
of biomimetic particles have focussed on the encapsulation of single model antigens with or without PAMPs, this 
study expands upon this concept, adding a second antigen spatially arranged so as to induce the relevant immune 
response i.e. a surface coated B cell antigen to readily enable BcR engagement and an encapsulated T cell antigen 
to prolong and augment antigen-presentation to TcR.
We chose to evaluate this approach using bovine virus diarrhoea virus (BVDV) as an example of a virus for 
which there is a need for improved vaccines. BVDV is an economically important pathogen that is endemic 
in cattle around the world. Infection by BVDV has a profound impact on the cattle industry as a result of pro-
duction and reproductive losses20. Currently both live attenuated and inactivated vaccines are used to control 
BVDV21. Live attenuated vaccines, although efficacious, have shortcomings such as the requirement for cold chain 
storage and transportation and a limited shelf life, safety concerns in pregnant cattle, immunosuppression and 
possible reversion to virulence by mutation or genetic recombination with wild-type viruses22. Inactivated vac-
cines are inherently safer but require frequent booster immunisations and often fail to provide foetal protection. 
Inactivated vaccines require administration with a strong adjuvant, which may carry risks, as exemplified by the 
PregSure® BVD vaccine which induced maternal alloantibodies linked to the fatal neonate-maternal incompat-
ibility syndrome, bovine neonatal pancytopenia23,24. It has been proposed that inactivated BVDV vaccines lack 
efficacy because of their failure to induce potent T cell responses possibly due to absence of non-structural pro-
teins, which have been shown to be targets of the T cell responses of immune cattle25,26. Attempts to develop subu-
nit vaccines have focused on the structural envelope glycoprotein E2, which is the dominant target of neutralising 
antibodies. A variety of approaches have been experimentally evaluated in cattle, including plasmid DNA, eukar-
yotically expressed recombinant antigen, individually or combined using heterologous DNA prime-protein boost 
regimes or via live viral vectors27–29. Assessment of the specificity of the T cell response to BVDV has been limited 
to a number of viral proteins (core, Erns, E2, NS2 and NS3) that have been shown to be recognised by T cells26,30. 
Since NS3 is highly conserved it has been proposed that the inclusion of NS3 protein may increase the efficacy of 
E2 subunit vaccines31. We therefore formulated a biomimetic BVDV particle containing NS3 protein, which this 
study confirmed by proteome-wide peptide library screening to be an immunodominant T cell antigen, alongside 
poly(I:C), and with the E2 glycoprotein coated on to the surface as the neutralising antibody target. The use of 
BVDV as the model virus allowed the testing of the vaccine for both immunogenicity and efficacy in the large 
mammalian definitive host species, something that is seldom achieved in bioengineering projects. In this model, 
we show that biomimetic particles induce antibody and T cell responses in cattle that afford significant protection 
against persistent infection following high dose heterologous viral challenge.
Results
Design and characterisation of biomimetic particle vaccine formulations. T cell responses of 
immune cattle to BVDV peptide pools were assayed by IFN-γ ELISA 21 days following BVDV Oregon C24V 
challenge infection (Fig. 1). Significant IFN-γ responses were observed against the peptide pools representing 
the E2, NS2, NS3 and NS5A proteins. Since the greatest responses were observed to the E2 peptide pool and 
the NS3-C peptide pool, which represents the C-terminal helicase domain of NS3, the NS3-helicase domain 
was selected for encapsulation within the particle while E2, was chosen to be coated on to the surface of the 
biomimetic particles (Fig. 2A). Both the BVDV antigen loaded particles (Vaccine-NP) and OVA loaded particles 
(Control-NP) used in this study were characterised in vitro (Fig. 2). The Vaccine-NPs were 200 nm larger than 
the Control-NP; with particles being sized at ≈500 nm and ≈300 nm, respectively (Fig. 2B). The Vaccine-NP 
also exhibited a higher polydispersity index value of 0.318 compared to the Control-NP, which were slightly 
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more uniform having a polydispersity index of 0.22. With regards to surface charge, after E2 coating, the vaccine 
particles increased their charge becoming effectively neutrally charged whereas the control particles remained 
negatively charged, possibly due to the capping of the terminal carboxyl group with tris (Fig. 2C). The surface 
E2 coating was also confirmed using flow cytometry (Fig. 2D). After being stained with a neutralising anti-E2 
mAb, the fluorescent labelling of the vaccine particles far exceeded that of the control particles with nearly 90% 
of the particles staining positive for E2 suggesting both an efficient coating and preservation and availability of 
the neutralising E2 epitope on the particle surface. Vaccine-NP showed an NS3 and poly(I:C) loading efficiencies 
of 20.5% and 17.7%, respectively, and an E2 coating efficiency of 16.2% (Fig. 2E). This translated to 163 µg NS3, 
45 μg E2 and 88 μg poly(I:C) in approximately 50 mg of PLGA particles per dose. Control-NP were loaded with 
poly(I:C) with a broadly similar efficiency and ovalbumin loaded at 20% (Data not shown). The poly(I:C) loading 
was variable between batches possibly because of the inherent solubility of poly(I:C) or alternately because the 
quantification relied on detecting the absence of poly(I:C) in wash supernatants rather than detecting the quantity 
loading.
Antigen-specific antibody and T cell IFN-γ responses following vaccination with biomimetic 
formulation. Serum antibody responses following vaccination and challenge were assessed by competition 
antibody ELISA against E2 and NS3 proteins and by determining virus neutralization titres (VNT) (Fig. 3). NS3 
and E2 specific antibody levels were determined as percent inhibition indices (Fig. 3A,B). In the IAV group, 
NS3-specific antibody values were significantly greater than the Control-NP group from day 7 post-boost (28 
days post-vaccination; dpv) until 58 dpv. The NS3 antibody response in the Vaccine-NP group showed a simi-
lar kinetic but with a lesser magnitude, being significantly greater than the Control-NP group from 35–58 dpv. 
Following IAV vaccination, significant E2 antibody values were detected on 21 dpv these were boosted by the 
second immunisation and remained significantly greater than those of the Control-NP group until 58 dpv (day 17 
post-challenge). The E2-specific response of the Vaccine-NP immunised group showed a similar trend to the IAV 
group with significant responses compared to the control group 35–58 dpv. The neutralising antibody response, as 
expected, mirrored that measured by E2 ELISA. However, inter-animal variance in VNTs meant that only the IAV 
group on days 47 and 58 dpv (days 6 and 17 post-challenge) had titres significantly greater than the Control-NP 
group. Anti-ovalbumin antibody responses could be detected in the Control-NP group but not the Vaccine-NP 
or IAV groups (data not shown).
T cell responses were assessed by measuring IFN-γ levels following ex vivo stimulation of PBMC with E2 and 
NS3 proteins (Fig. 4). In both IAV and Vaccine-NP groups, IFN-γ responses to stimulation with both proteins 
were detected post-booster immunisation and further increased upon challenge. However, substantial variation 
in the magnitude of responses of individual animals in both groups meant that these responses did not achieve 
statistical significance.
Assessment of vaccine-induced protection against BVDV challenge infection. Protection against 
BVDV challenge infection was assessed by measurement of viral antigen (Erns) and viral RNA in peripheral blood. 
As shown in Fig. 5, blood antigen levels became detectable at day 6 post-challenge and reached their peak at day 
9 after which they began to decline. This trend was consistent between all three groups, however, there were dif-
ferences between each group; the IAV group had the least blood antigen (statistically significant on day 6 and 9 
Figure 1. Recognition of BVDV-1 proteins by T cells from immune cattle. PBMC from BVDV-immune cattle 
challenged by experimental infection with BVDV Oregon C24v (n = 5) were isolated on day 21 post-challenge, 
and stimulated in vitro with synthetic peptides pooled to represent BVDV-1 proteins. PBMC cultured in media 
alone were included as a negative control. IFN-γ secreted into culture supernatants was quantified by ELISA 
after 48 hours. Mean data are presented and error bars show the SEM. Values for virus and peptide pool-
stimulated conditions were compared to the unstimulated (media) control using a one-way ANOVA followed 
by a Dunnett’s multiple comparison test; ****p < 0.0001, and *p < 0.05.
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post-challenge), the Vaccine-NP group had an intermediate level whilst the Control-NP group had the highest. 
The levels of BVDV RNA in blood followed a similar trend to that observed for viral antigen. They peaked at day 9 
post-challenge in the case of the Vaccine and Control-NP groups; however, there were significantly higher levels 
of BVDV RNA in the Control-NP group compared to both Vaccine-NP and IAV groups at this peak. The IAV 
Figure 2. In vitro characterisation of nanoparticulate formulations of BVDV antigens. PLGA nanoparticles 
were synthesised as described with either BVDV antigens (Vaccine-NP) or OVA (Control-NP). A graphical 
representation of Vaccine-NP is shown in (A). Particles were analysed with dynamic light scattering to assess 
size (B) and charge (C); data represents the pooled particles used in this study read in triplicate runs. Size bars 
are annotated with polydispersity indices; error bars represent the SD. The size and charge of Vaccine-NP and 
Control-NP were compared by a student’s t-test (*p < 0.05). Surface coating of nanoparticles with BVDV E2 
was determined by flow cytometry following staining of Control-NP (red) and Vaccine-NP (blue) with a BVDV 
E2 specific mAb followed by anti-mouse IgG1-APC (D). Calculation of nanoparticle loading and coating on a 
per dose basis and estimate of loading/coating efficiency (E). Mean data of all particle batches used in this study 
(n = 12) are presented ± SD.
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group showed a peak in viral RNA on day 6-post challenge. Interestingly, all groups showed a second peak in viral 
RNA, which was particularly apparent in the Vaccine-NP and IAV group, where the two groups show the same 
trend albeit offset. Viral RNA was cleared from the blood of the Vaccine-NP and IAV groups on day 21 and 18, 
respectively, whereas, viral RNA was still detectable in the blood of Control-NP animals at the termination of the 
experiment (day 24 post-challenge), which is in line with another observation the more pathogenic strains such 
as Ho916 induce a persistent infection in post-natal infection32.
Discussion
Subunit vaccines based on a single protein have been used successfully to protect against a number of diseases. 
However, for diseases against which there is no vaccine or traditional vaccine approaches are suboptimal, it is 
likely that more rationally designed formulations are required. These formulations should take into account the 
physical nature of the antigen and how it interacts with the immune system. Since the licensure of GSK’s RTS,S, 
a malarial protein construct expressed on the surface of the hepatitis B viral capsid as a VLP, there has been a 
growing interest in using particulates as antigen carriers to induce more potent immune responses33. However the 
antigen need not be expressed as a fusion protein, it may simply be chemically linked to VLPs post-production. 
This strategy greatly enhances the immunogenicity when compared to free protein in a number of models34,35. 
The present study took an alternate approach using polymeric nanoparticles as the antigen carrier, in combination 
Figure 3. BVDV antigen-specific antibody responses following vaccination with nanoparticulate formulation 
of BVDV antigens and challenge infection. Sera from calves vaccinated with either inactivated BVDV vaccine 
(IAV) (squares), Vaccine-NP (triangles) or Control-NP (circles) were collected longitudinally over the course 
of vaccination and BVDV challenge. NS3 (A) and E2 (B) specific antibodies were measured by competitive 
ELISA and BVDV-neutralising titres determined by virus-neutralization assay (C). Mean data for each group 
(n = 6) are presented, error bars represent SEM and statistical analysis was performed using a two-way ANOVA 
followed by a Tukey’s multiple comparison test; statistically significant differences between the Control-NP 
group and the IAV and Vaccine-NP groups are indicated as ‘a’ and ‘b’, respectively. Booster immunisation and 
BVDV challenge infections on days 21 and 41 post-vaccination are indicated.
Figure 4. BVDV antigen-specific T cell IFN-γ responses following vaccination with nanoparticulate 
formulation of BVDV antigens and challenge infection. PBMCs from calves vaccinated with either inactivated 
BVDV vaccine (IAV) (squares), Vaccine-NP (triangles) or Control-NP (circles) were collected longitudinally 
over the course of vaccination and BVDV challenge, stimulated with recombinant BVDV E2 (A) or NS3 helicase 
(B) proteins. After 48 hours, IFN-γ in culture supernatants was measured by ELISA. Mean unstimulated-
corrected data for each group (n = 6) are presented, error bars represent SEM. Booster immunisation and 
BVDV challenge infections on days 21 and 41 post-vaccination are indicated.
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with recombinant BVDV antigens, E2 and NS3, and the molecular adjuvant poly(I:C) and compared this for-
mulation to a commercial inactivated vaccine. While production of VLPs requires expensive industrial scale 
fermenters to produce sufficient quantities of inoculum, polymers such as PLGA particles can be produced using 
inexpensive, relatively simple methods and antigen can be conjugated post-synthesis. Furthermore, they may 
allow for a more readily customisable approach such as the inclusion of specific adjuvants. A rational approach 
was taken to the design of the vaccine particles incorporating multiple antigens. With regards to BVDV antigens, 
we have identified and utilised the two immunodominant T cell and B cell target antigens, NS3 helicase and E2 
(Fig. 1 and26,36–38); other antigens could be included in future studies such as the NS3 N-terminal protease domain 
or the full-length NS3 protein, however, this is particularly hard to express as a recombinant protein. BVDV E2 
protein was selected based on its ability to induce neutralising antibodies39,40. This study also confirmed NS3 as 
a second T cell antigen for inclusion in the formulation. PLGA was chosen as the particle shell due to its safety 
profile and ease of handling. Poly(I:C) was selected as the molecular adjuvant due its close association with viral 
infection, we speculated it may be able to induce an antiviral Th1/cytotoxic skewed immune response, similar 
to that of a virus, furthermore BVDV has been shown to modify TLR3 expression potentially as an immuno-
logical escape mechanism41–43. We observed a relatively low loading of antigen, however, this was in keeping 
with our previous results44, which we speculate is due to our selected process parameters. Indeed, other studies 
have reported a range of antigen loading efficiencies8,45,46. Future work should consist of improving the method 
to enable better loadings. The Vaccine-NP were slightly larger than the Control-NP, we believe this represents, 
firstly, physical differences between the encapsulated antigens and, secondly, the additional coated antigen whose 
structure has not been determined in this setting. In this study, we were unable to compare the vaccine formula-
tions with unencapsulated antigens and adjuvant due to practical limitations, but the antigens we selected have 
previously been tested as protein vaccines with improved efficacy when combined47. Given the large amount of 
antigen used, a dose-response study will be necessary to determine the optimal amount of antigen to use.
In terms of magnitude of immune responses the Vaccine-NP did not perform as well as the commercial 
inactivated vaccine. This is likely due to the inclusion of the powerful adjuvant Quil-A in the inactivated formu-
lation which cannot be used in humans due to adverse reactions induced48. In contrast, most studies generally 
compare experimental vaccines to a unadjuvanted formulation or a formulation containing Alum, which is not 
as potent and polarises towards Th2 responses. To elucidate the contribution of the biomimetic formulation to 
the immunogenicity a more informative comparison would be to compare the soluble form of the antigens to the 
spatially arranged rationally designed particle. However, in terms of translational potential we felt comparing 
the biomimetic particle to the commercial product would be more relevant. Responses may be enhanced, with 
the use of better adjuvants or immuno-stimulating polymers or combinations of such which stimulate broader 
immune responses. Also, combinations of TLR agonists may act synergistically in triggering the desired T cell or 
humoral immune responses49. A recent study, demonstrated enhanced antibody responses to synthetic nanopar-
ticles containing antigen and TLR-4 and TLR-7 ligands compared to nanoparticles containing antigen and indi-
vidual TLR ligands12. There is no reason why Quil-A or a safer derivative such as QS-2150 could not be included 
in a biomimetic nanoparticle or even in the more conventional, unencapsulated form alongside the particle, as 
has been done with alum51. The molecular adjuvant poly(I:C) used in the reported biomimetic formulation is 
currently being extensively studied and it is it highly plausible that poly(I:C) will be subsequently approved for 
both human and veterinary use52,53.
Figure 5. Detection of BVDV in the blood of vaccinated animals following challenge infection. Following 
BVDV-1 challenge infection, blood samples from inactivated BVDV vaccine (IAV) (squares), Vaccine-NP 
(triangles) or Control-NP (circles) vaccinated calves were assessed for BVDV Erns antigen by ELISA (A) and 
BVDV RNA by quantitative RT-PCR (B). Mean data for each group (n = 6) are presented, error bars represent 
SEM and statistical analysis was performed using a two-way ANOVA followed by a Tukey’s multiple comparison 
test; statistically significant differences between Control-NP group and the IAV and Vaccine-NP groups are 
indicated as ‘a’ and ‘b’, respectively. Horizontal dashed lines show the assay cut-off for antigen positivity (COD 
>0.3) and detection limit (3.55 TCID50) for ELISA and RT-PCR assays, respectively.
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Biomimetic vaccine formulations offer a promising mode of vaccination that can be improved by use of better 
adjuvants, greater consideration of the location of antigen (coated or encapsulated), as well as targeted delivery 
of antigen and adjuvant to dendritic cells. In addition to the adaptability of this method of antigen delivery, other 
advantages such as the relative safety and capacity for differentiating infected from vaccinated animals (DIVA) 
are offered by the use of subunit antigens. Whether chemical conjugation of antigen to PLGA can match the 
immunogenicity warranted by antigen conjugated to VLPs in a similar fashion has yet to be demonstrated con-
clusively, nonetheless the prospect is exciting. We believe that biomimetic nanoparticulate formulations could be 
developed as both veterinary and humans vaccines, although the regulatory requirements will differ. In recent 
years, a number of studies have been published which have evaluated nanoparticulate delivery of vaccines for a 
number of major livestock pathogens in both cattle (foot-and-mouth disease virus; bovine parainfluenza-3 virus; 
bovine respiratory syncytial virus54–57) and pigs (swine influenza A virus; porcine reproductive and respiratory 
syndrome virus-1 and −258–60). The selection of BVDV as the ‘model’ virus allowed us to test the biomimetic 
vaccine for both immunogenicity and efficacy in the large mammalian definitive host species, something that is 
seldom achieved in bioengineering projects. Since large animal models have been shown to more accurately pre-
dict vaccine outcome in humans than do other models61, our model may provide useful insights to guide human 
vaccine development.
Materials and Methods
Proteins and Peptides. The helicase domain of NS3 protein (BVDV polyprotein amino acids 1782–2272) 
was cloned from BVDV-1a strain CP7 (GenBank accession no. U63479.162) and respective plasmid pL200 was 
expressed as a C-terminal fusion protein with a 12 His-tag in Escherichia coli RosettaTM cells (Novagen) and puri-
fied via HisTrap HP columns (GE Life Science, Freiburg, Germany) using native buffer (300 mM NaCl, 150 mM 
NaH2PO4, pH 7.4) conditions. Protein was eluted with gradients of 100–500 mM imidazole dissolved in the same 
buffer. Protein purity was assessed by SDS-PAGE and shown to be >90%. The ectodomain of E2 protein from 
BVDV-1a NCP7 and NADL (polyprotein amino acids 1782–2272) was expressed in insect cells. Briefly, the cor-
responding genes were cloned into a modified Drosophila S2 expression vector and transfection was performed 
as described before63. For large-scale production, cells were induced with 4 μM CdCl2 at a density of approxi-
mately 7 × 106 cells/ml for 7 days, pelleted, and the soluble ectodomain was purified by affinity chromatography 
from the supernatant using a StrepTactin Superflow column followed by size exclusion chromatography using a 
Superdex200 column in 10 mM TRIS pH8, 150 mM NaCl. A library of overlapping 16mer peptides, offset by 4 
amino acids spanning the entire length of the polyprotein of the BVDV-1 strain, Oregon C24V (GenBank acces-
sion no. AF091605), was synthesised by Pepscan Systems B.V. (Lelystad, The Netherlands) and peptides pooled to 
represent the BVDV proteins as described previously64.
Viruses. The prototype BVDV-1a Oregon C24V strain and a BVDV-1a clinical field isolate Ho91665 were 
propagated in vitro by inoculation of foetal bovine turbinate (BT) cell monolayers (Cell and Tissue Culture Unit, 
APHA, Addlestone, UK). BT cells were maintained in Minimum Essential Medium (MEM) with 7.5% sodium 
carbonate, 5% lactalbumin hydrolysate, 1 mM sodium pyruvate, 2 mM glutamine, 100 U/ml penicillin, 100 μg/
ml streptomycin and 20 μg/ml nystatin (all Invitrogen, Life Technologies, Paisley, UK) and 10% BVDV-free foetal 
bovine serum (FBS; Autogen Bioclear, Calne, UK) (BT medium). After 4 days, the supernatant was collected and 
pooled with a freeze-thawed cell lysate. The resultant pool was clarified by centrifugation at 524 × g for 10 min-
utes, aliquoted and stored at −80 °C. Virus titres were determined as the median (50%) tissue culture infectious 
dose (TCID50) using the Spearman-Kärber method66 following immunoperoxidase staining67. Mock virus super-
natant was prepared in an identical manner from uninfected BT cells.
Peptide epitope screening. All animal work was approved by the Animal and Plant Health Agency’s 
Institutional Animal Care and Use Committee and all procedures were conducted in accordance with the 
UK Animals (Scientific Procedures) Act 1986. To screen for BVDV T cell antigens, five 3–4 month old 
Holstein-Friesian calves were inoculated intranasally (i.n.) with 107 TCID50 of BVDV Oregon C24V (2 ml divided 
equally between each nostril and administered using a mucosal atomization device MAD-300, Wolfe Tory 
Medical, USA). Animals were monitored for clinical signs of infection, viraemia and heparinised blood samples 
collected to assess T cell responses to BVDV peptide pools.
Vaccine formulations. A formulation of PLGA (Resomer RG502 H, 50:50 LA:GA molar ratio, Mw 7–17 
KDa, Sigma-Aldrich, Poole, UK) nanoparticles encapsulating BVDV-1 CP7 NS3 helicase domain and poly(I:C) 
(Sigma-Aldrich, Poole, UK) and coated with BVDV-1 NCP7 and NADL baculovirus-derived E2 protein ecto-
domain (Vaccine-NP; approximately 150 µg NS3, 50 µg E2 and 80 μg poly(I:C) per dose) was prepared as previ-
ously described44. Particles were synthesised sequentially; firstly, NS3 loaded particles were made, NS3 loading 
was then determined by hydrolysis of a representative fraction of particles with 0.1 M NaOH, and following 
neutralisation with 0.1 M HCl the protein content was determined using BCA assay (Thermo Fisher Scientific). 
E2 was then coated using a previously described method44 and coated protein was determined by subtracting 
protein content post-coating from the protein content prior to coating. E2 coating of particles was additionally 
assessed by staining particles with an E2-specific monoclonal antibody (clone WB214, APHA) and flow cytomet-
ric analysis using a MACSQuant Analyzer flow cytometer (Miltenyi Biotec, Bisley, UK)44. The poly(I:C) loading 
was calculated by subtracting the quantity of poly(I:C) detected in particle wash supernatant, as determined by 
absorbance OD240, from the starting quantity. PLGA nanoparticles similarly formulated with poly(I:C) and oval-
bumin protein (Sigma-Aldrich) were used as a negative control (Control-NP). Particle size and surface charge 
were assessed by hydrodynamic diameter and zeta potential measurements using a Zetasizer 3000 (Malvern 
Instruments, Malvern, UK). A licensed inactivated BVDV vaccine (IAV), Bovidec® (Novartis Animal Health, 
www.nature.com/scientificreports/
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Camberley, United Kingdom), was used as a reference standard for both immunogenicity and efficacy. According 
to the manufacturer’s specifications, Bovidec consists of an inactivated BVDV-1a strain, KY1203nc68 in MEM 
(5 × 106 TCID50 per 4 ml dose), which is adjuvanted with Quil-A (1 mg per dose).
Vaccination and challenge of cattle. To evaluate vaccines, eighteen 6–8 month old male Holstein-Friesian 
calves were pre-tested for the absence of BVDV antibody and antigen and randomly assigned into three experi-
mental groups prior to vaccination. Group sizes of 6 were calculated, using data from a previous published BVDV 
E2 vaccine trial40, to be able to detect significant differences in neutralising antibody titres between groups with 
92% power and 95% confidence. Calves (n = 6) received a primary subcutaneous inoculation of Vaccine-NP or 
Control-NP in 2 ml or IAV in 4 ml. A similar booster inoculation was given at 21 days post-vaccination (dpv). On 
41 dpv, all cattle received an intranasal inoculation with 5 × 106 TCID50 BVDV-1a Ho916 in 2 ml BT medium, 
which was confirmed by back titration. Clinical scores and rectal temperatures were monitored prior to viral 
challenge and on a daily basis subsequently32. Blood samples were collected longitudinally over the course of 
vaccination and challenge to assess serum antibody and peripheral blood T cell IFN-γ responses, and to monitor 
for viral loads.
Detection of antigen-specific and virus-neutralising antibody responses. Competitive ELISA 
kits were used for the detection of antibodies against NS3 (Pourquier® ELISA BVD p80, Institut Pourquier, 
Montpellier, France) and E2 (VDPro® BVDV, Jeno Biotech Inc., Chuncheon, Republic of Korea) according to the 
manufacturer’s instructions. To determine virus neutralising antibody titres, test sera were heat inactivated for 
30 minutes at 56 °C after which a two-fold dilution in BT medium was added to duplicate wells of a flat-bottomed 
96-well plate. Positive and negative control sera were also tested. An equal volume containing 100 TCID50 of 
BVDV-1 Ho916 was added and incubated for 1 hour at 37 °C. BT cells were then added (1.5 × 104) and incubated 
at 37 °C for 5 days, after which immunoperoxidase staining for virus was conducted as described previously67. 
Neutralising titres were calculated as reciprocal of the highest serum dilution that inhibited virus growth by 50% 
using the Spearman–Kärber method.
Detection antigen specific T cell IFN-γ responses. Peripheral blood mononuclear cells (PBMC) 
isolated by density centrifugation using Histopaque 1.077 (Sigma-Aldrich) were suspended at a density of 
5 × 106 cells/ml in RPMI-1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 20 mM HEPES, 100U/
ml penicillin and 100 μg/mL streptomycin, and 100 μl transferred to wells of 96 well round-bottom plates. Cells 
were stimulated in duplicate wells with 100 μl of peptide pools with each peptide at 2 μg/ml or recombinant 
E2 and NS3 proteins at 10 μg/ml. Medium alone was used as negative controls. The cells were incubated at 
37 °C for 48 hours after which cell-free supernatants were harvested after centrifugation and stored at −80 °C 
until analysed. Interferon-gamma (IFN-γ) in culture supernatants was measured using ELISA. Briefly, plates 
(ViewPlate-96, PerkinElmer, Seer Green, UK) were coated with mouse anti-bovine IFN-γ mAb (clone CC330, 
BioRad Antibodies, Oxford, UK) at 5 μg/ml in 0.05 M carbonate/bicarbonate coating buffer (pH 9.6) (Sigma). 
Following overnight incubation plates were blocked with 1% bovine serum albumin (BSA) and 0.05% Tween-20. 
Test supernatant was added to duplicate wells. A two-fold serial dilution of recombinant bovine IFN-γ (BioRad 
Antibodies) in cRPMI, starting at 50 ng/ml, and medium alone was added as standard/positive and negative con-
trols respectively. The plates were washed and biotin-conjugated mouse anti-bovine IFN-γ mAb at 5 μg/ml (clone 
CC302, BioRad Antibodies) added. The plates were incubated and washed as above and streptavidin conjugated 
horseradish peroxidise (SA-HRP; GE Healthcare, Little Chalfont, UK) was added. After a final wash, Supersignal® 
ELISA Femto Substrate (Thermo Fisher Scientific) was added according to manufacturer’s data sheet, the relative 
light units (RLU) measured on a luminometer (≈425 nm) (Victor™ × 4 Multiplate Plate Reader; Perkin Elmer, 
Seer Green, UK).
Assessment of BVDV viraemia post-challenge. The BVDV envelope RNase glycoprotein, Erns, was 
detected in heparinised blood samples post-challenge using the HerdChek® BVDV Antigen/Serum Plus ELISA 
kit according to the manufacturer’s instructions (IDEXX Switzerland AG, Liebefeld-Bern, Switzerland). BVDV 
RNA was extracted from EDTA blood samples post-challenge using the QIAamp Viral RNA Mini Kit (Qiagen, 
Crawley, UK) as described by the manufacturer. BVDV RNA content measured using a single tube nested quan-
titative RT-PCR (qRT-PCR) TaqMan® assay as described69. Signal was detected using a Stratagene MX3000 P 
Real-Time PCR machine (Agilent Technologies, La Jolla, CA, USA) and data analysed on the MX Pro 4.1.0c 
Software (Agilent Technologies). Relative quantities of viral RNA in samples were quantified by interpolation 
against a 10-fold dilution of RNA extracted from an equivalent volume of virus (BVDV-1a Oregon C24V) of 
known titre (standard range from 107.55 to 100.55 TCID50/ml)70.
Statistical analysis. GraphPad Prism 6.01 (GraphPad Software, La Jolla, USA) was used for graphical and 
statistical analysis of data sets. A one-way or two-way analysis of variance (ANOVA) was employed to analyse 
fixed effects on different traits with post-hoc tests as detailed in figure legends. A p value < 0.05 was considered 
statistically significant.
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